AZN ASTRAZENECA PLC IFRS
Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2021Q12021-03-31 | 2020Q42020-12-31 | 2020Q32020-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.46B | $12.94B | $11.42B | $10.77B | $8.22B | $7.26B | $7.01B | $6.52B |
| Cost of revenue | $2.47B | $2.18B | $1.96B | $3.00B | $2.19B | — | — | — |
| Gross profit | $11.98B | $10.76B | $9.46B | $7.77B | $6.03B | — | — | — |
| R&D expense | $3.55B | $3.01B | $2.67B | $2.55B | $1.83B | — | — | — |
| SG&A expense | $4.86B | $4.93B | $4.99B | $4.68B | $3.10B | — | — | — |
| Operating income | $3.51B | $2.75B | $2.46B | $539.00M | $1.13B | — | — | — |
| Interest expense | $439.00M | $443.00M | $431.00M | $311.00M | $326.00M | — | — | — |
| Pretax income | $3.13B | $2.40B | $2.09B | $247.00M | $764.00M | — | — | — |
| Income tax | $679.00M | $469.00M | $268.00M | -$113.00M | $214.00M | — | — | — |
| Net income | $2.45B | $1.93B | $1.82B | $360.00M | $550.00M | — | — | — |
| EPS (basic) | 1.58 | 1.24 | 1.17 | 0.23 | 0.42 | — | — | — |
| EPS (diluted) | 1.57 | 1.24 | 1.17 | 0.23 | 0.42 | — | — | — |
| Weighted avg. shares (diluted) | 1.56B | 1.56B | 1.56B | 1.56B | 1.32B | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.06B | $6.92B | $5.66B | $4.82B | $15.57B | — | $7.83B | — |
| Short-term investments | $50.00M | $160.00M | $148.00M | $70.00M | $62.00M | — | $160.00M | — |
| Receivables | $14.17B | $11.05B | $11.09B | $8.91B | $6.36B | — | $7.02B | — |
| Inventory | $6.47B | $5.67B | $5.05B | $6.22B | $4.76B | — | $4.02B | — |
| Current assets | $28.94B | $25.39B | $22.84B | $20.92B | $27.27B | — | $19.54B | — |
| PP&E, netmay include right-of-use assets (IFRS) | $11.64B | $9.63B | $8.68B | $8.72B | $8.36B | — | $8.25B | — |
| Goodwill | $21.22B | $21.06B | $19.96B | $19.82B | $11.80B | — | $11.85B | — |
| Intangibles | $37.92B | $39.43B | $38.33B | $39.90B | $20.01B | — | $20.95B | — |
| Total assets | $112.42B | $104.34B | $96.54B | $96.58B | $73.64B | — | $66.73B | — |
| Current liabilities | $33.54B | $28.57B | $26.38B | $21.82B | $22.22B | — | $20.31B | — |
| Short-term debt | $6.49B | $5.07B | $4.56B | $2.16B | $2.70B | — | $2.19B | — |
| Long-term debt | $24.71B | $27.23B | $24.33B | $26.46B | $24.11B | — | $17.50B | — |
| Total debt | $31.21B | $32.29B | $28.89B | $28.62B | $26.80B | — | $19.70B | — |
| Total liabilities | $67.61B | $64.74B | $59.13B | $60.63B | $57.95B | — | $51.09B | — |
| Shareholders' equity | $44.72B | $39.51B | $37.39B | $35.93B | $15.68B | — | $15.62B | — |
| Net debt | $24.15B | $25.38B | $23.22B | $23.81B | $11.24B | — | $11.87B | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.